A Method for the Establishment of Human Lung Adenocarcinoma Patient-Derived Xenografts in Mice.

Szczegóły
Abstrakt

Tytuł:: A Method for the Establishment of Human Lung Adenocarcinoma Patient-Derived Xenografts in Mice.
Autorzy:: Lundy J; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia.; Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
Jenkins BJ; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia.; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia.
Saad MI; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia. .; Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia. .
Źródło:: Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2021; Vol. 2279, pp. 165-173.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Totowa, NJ : Humana Press
Original Publication: Clifton, N.J. : Humana Press,
MeSH Terms:: Adenocarcinoma of Lung*/metabolism
Adenocarcinoma of Lung*/pathology
Lung Neoplasms*/metabolism
Lung Neoplasms*/pathology
Neoplasm Transplantation*
Animals ; Female ; Heterografts ; Humans ; Male ; Mice ; Mice, Inbred NOD ; Mice, SCID
References:: Wang D, Pham NA, Tong J et al (2017) Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Int J Cancer 140(3):662–673. (PMID: 10.1002/ijc.30472)
Jiang Y, Zhao J, Zhang Y et al (2018) Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study. J Transl Med 16(1):138. (PMID: 10.1186/s12967-018-1516-5)
Fichtner I, Rolff J, Soong R et al (2018) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14(20):6456–6468. (PMID: 10.1158/1078-0432.CCR-08-0138)
Kim M, Mun H, Sung CO et al (2019) Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun 10(1):1–15. (PMID: 10.1038/s41467-018-07882-8)
Sachs N, Papaspyropoulos A, Zomer-van Ommen DD et al (2019) Long-term expanding human airway organoids for disease modeling. EMBO J 38(4):e100300. (PMID: 10.15252/embj.2018100300)
Reyal F, Guyader C, Decraene C et al (2012) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14(1):R11. (PMID: 10.1186/bcr3095)
Hidalgo M, Amant F, Biankin AV et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013. (PMID: 10.1158/2159-8290.CD-14-0001)
Johnson JR, Hammond WG, Benfield JR et al (1995) Successful xenotransplantation of human lung cancer correlates with the metastatic phenotype. Ann Thorac Surg 60(1):32–37. (PMID: 10.1016/S0003-4975(95)00320-7)
Perez-Soler R, Kemp B, Wu QP et al (2000) Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6(12):4932–4938. (PMID: 11156254)
Dong X, Guan J, English JC et al (2010) Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16(5):1442–1451. (PMID: 10.1158/1078-0432.CCR-09-2878)
Ilie M, Nunes M, Blot L et al (2015) Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer Med 4(2):201–211. (PMID: 10.1002/cam4.357)
Merk J, Rolff J, Becker M et al (2009) Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 36(3):454–459. (PMID: 10.1016/j.ejcts.2009.03.054)
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388. (PMID: 10.1056/NEJMoa0909530)
Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394. (PMID: 10.1056/NEJMoa1214886)
Sundar R, Chénard-Poirier M, Collins DC et al (2017) Imprecision in the era of precision medicine in non-small cell lung cancer. Front Med 4:39. (PMID: 10.3389/fmed.2017.00039)
Zhang Y, Yao K, Shi C et al (2015) 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells. Oncotarget 6(42):44274–44288. (PMID: 10.18632/oncotarget.6236)
Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. (PMID: 10.1056/NEJMoa1606774)
Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301. (PMID: 10.1056/NEJMoa1716948)
Hellmann MD, Paz-Ares L, Bernabe-caro R et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381(21):2020–2031. (PMID: 10.1056/NEJMoa1910231)
Ma Y, Zhang P, An G et al (2016) Induction of patient-derived xenograft formation and clinical significance of programmed cell death ligand 1 (PD-L1) in lung cancer patients. Med Sci Monit 22:4017–4025. (PMID: 10.12659/MSM.900661)
Pearson T, Greiner DL, Shultz LD (2008) Creation of “humanized” mice to study human immunity. Curr Protoc Immunol 81(1):15–21. (PMID: 10.1002/0471142735.im1521s81)
Bosma GC, Custer RP, Bosma MJ (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301(5900):527–530. (PMID: 10.1038/301527a0)
Ito M, Hiramatsu H, Kobayashi K et al (2002) NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175–3182. (PMID: 10.1182/blood-2001-12-0207)
Contributed Indexing:: Keywords: Humanization; Lung adenocarcinoma; NOD scid gamma mouse; Non-small cell lung cancer; Patient-derived xenograft
Entry Date(s):: Date Created: 20210308 Date Completed: 20210401 Latest Revision: 20210401
Update Code:: 20240105
DOI:: 10.1007/978-1-0716-1278-1_13
PMID:: 33683693
: Czasopismo naukowe

Patient-derived xenografts (PDXs) are created by implanting human tumor tissue or cells into immunodeficent mice, and enable the study of tumor biology, biomarkers and response to therapy in vivo. This chapter describes a method for lung adenocarcinoma (LAC) PDX generation using subcutaneous implantation of tumor tissue and cell suspensions and incorporating the humanization of PDX models by reconstitution with human immune cells.

Informacja